Lactobacillus plantarum 299v reduces colonisation of Clostridium difficile in critically ill patients treated with antibiotics
Författare
Summary, in English
Background: The incidence of Clostridium difficile-associated disease (CDAD) in hospitalised patients is increasing. Critically ill patients are often treated with antibiotics and are at high risk of developing CDAD. Lactobacillus plantarum 299v (Lp299v) has been found to reduce recurrence of CDAD. We investigated intensive care unit (ICU) patients regarding the impact of Lp299v on C. difficile colonisation and on gut permeability and parameters of inflammation and infection in that context.
Methods: Twenty-two ICU patients were given a fermented oatmeal gruel containing Lp299v, and 22 received an equivalent product without the bacteria. Faecal samples for analyses of C. difficile and Lp299v were taken at inclusion and then twice a week during the ICU stay. Other cultures were performed on clinical indication. Infection and inflammation parameters were analysed daily. Gut permeability was assessed using a sugar probe technique.
Main Results: Colonisation with C. difficile was detected in 19% (4/21) of controls but in none of the Lp299v-treated patients (p < 0.05).
Conclusions: Enteral administration of the probiotic bacterium Lp299v to critically ill patients treated with antibiotics reduced colonisation with C. difficile.
Trial registration: Current Controlled Trials ISRCTN85655545
Methods: Twenty-two ICU patients were given a fermented oatmeal gruel containing Lp299v, and 22 received an equivalent product without the bacteria. Faecal samples for analyses of C. difficile and Lp299v were taken at inclusion and then twice a week during the ICU stay. Other cultures were performed on clinical indication. Infection and inflammation parameters were analysed daily. Gut permeability was assessed using a sugar probe technique.
Main Results: Colonisation with C. difficile was detected in 19% (4/21) of controls but in none of the Lp299v-treated patients (p < 0.05).
Conclusions: Enteral administration of the probiotic bacterium Lp299v to critically ill patients treated with antibiotics reduced colonisation with C. difficile.
Trial registration: Current Controlled Trials ISRCTN85655545
Avdelning/ar
- Anestesiologi och intensivvård
- Infectious Diseases Research Unit
- Kirurgi
- Avdelningen för livsmedel och läkemedel
Publiceringsår
2008
Språk
Engelska
Sidor
1096-1102
Publikation/Tidskrift/Serie
Acta Anaesthesiologica Scandinavica
Volym
52
Issue
8
Länkar
Dokumenttyp
Artikel i tidskrift
Förlag
Wiley-Blackwell
Ämne
- Anesthesiology and Intensive Care
Nyckelord
- gut permeability
- critical illness
- Clostridium difficile
- ICU
- Lactobacillus plantarum 299v
- Clostridium difficile-associated disease
- probiotics
- CDAD
- immune function.
Status
Published
Forskningsgrupp
- Infectious Diseases Research Unit
- Surgery
ISBN/ISSN/Övrigt
- ISSN: 0001-5172